TAKE Solutions Ltd. (BSE: 532890), leaders in Life Sciences and Supply Chain Management (SCM) products, announced that the company has entered into strategic partnership with Reliance Life Sciences to supply its unique and innovative PharmaReady eCTD, SPL and PPM modules. The seamless integration of TAKE Solutions’ technologically advanced products will not only support Reliance Life Sciences in strengthening product development services; but these customized IT solutions will also add a cutting-edge finesse to the present line of business. With its strong background and industry knowledge, TAKE’s Warehousing & Clinical Systems Development and Integration tools will deliver a full spectrum of Information Management Services, leveraging on industry data standards to streamline the clinical information lifecycle. “We were looking out for a submission solution that can address our current and future requirement of our organization that enables our regulatory submissions. Also, in addition to software solutions, we wanted to partner with an organization that understands our business dynamics, and could work with Reliance Life Sciences to enhance the business process and solution set over the time to come. After a detailed market search, and understanding of the solutions available, TAKE Solutions emerged as a definite choice for us as the solution set offered us flexibility and options for customization, while meeting the core requirements. Also, TAKE Solutions as an organization has the right credentials, industry expertise and resource strength that we were looking for.” said Mr. Gopal Rangaraj, Vice President IT, Reliance Life Sciences Pvt. Ltd. “We are extremely pleased to partner with Reliance Life Sciences. Our engagement with such a credible and commended Life Sciences solution major is evidence of TAKE Solutions’ comprehensive understanding of the business, the challenges and proven track record of providing intelligent and innovative clinical regulatory solutions,” said, Mr. Ramesh L, Vice President – Sales, Life Sciences APAC, TAKE Solutions Ltd. Notes to EditorAbout Reliance Life Sciences Reliance Life Sciences, is a new millennium initiative of the Reliance Group. Reliance Group is the largest private sector enterprise in India, participating in businesses in the energy and materials value chain, with group revenues of USD 30 billion. The flagship company, Reliance Industries Limited, is a Fortune Global 500 company, and ranks 103rd amongst the world’s top companies in terms of revenues. Reliance Life Sciences is developing business opportunities in the domains of medical, plant and industrial biotechnology. From a domain perspective, these opportunities cover Biopharmaceuticals, Pharmaceuticals, Clinical Research Services, Regenerative Medicine, Molecular Medicine, Novel Therapeutics, BioFuels, Plant Tissue Culture, Plant Metabolic Engineering and Industrial Biotechnology. From an integration perspective, these opportunities encompass Repositories, Research, Process Development, Pre-clinical Studies, Clinica; Trials, Commercial-scale Manufacture and Marketing, all of which are carried out in-house. About TAKE Solutions TAKE Solutions is a leading software and services provider with domain expertise in Life Sciences (LS) and Supply Chain Management (SCM). With intellectual property assets embedded within its technology solutions, and with a set of best practices executed by skilled domain and technology professionals, TAKE is constantly looking at opportunities to drive efficiencies for its clients’ businesses. Headquartered in Chennai, TAKE primarily drives its SCM Domain Excellence Centre and Global Delivery Centre from India. Company has strong presence in the USA with Life Sciences Domain Excellence centres located in Princeton, New Jersey. The Company conducts business today with more than 390 customers worldwide. TAKE has been recognized as India’s 10th fastest growing technology company by Deloitte Technology Fast 50 India 2008 and has also been assessed at Level 5 of the Capability Maturity Model Integration (CMMI) & Level 3 of the People Capability Maturity Model, Software Engineering Institute, Carnegie Mellon University, USA. TAKE is also a Microsoft Gold Certified Partner, a Charter Member of the Microsoft BioIT Alliance, and along with its subsidiary (ACI), is a Registered CDISC Solution Provider, with recognized industry leadership in Microsoft-based Solutions, Regulated Life Sciences, and Supply Chain Management.

Source:http://news-views.in/reliance-life-sciences-and-take-solutions-enter-into-a-strategic-alliance/

History:
Founding –

Reliance Life Sciences was incorporated in the year 2001 and is an initiative of the Reliance Group of companies. Reliance Life Sciences was initiated in order to develop business opportunities on the medical, plant and industrial biotechnology front. RLS aspires to be the most diverse and integrated biotechnology initiative developed in the world. The main campus for Reliance Life Sciences is at the Dhirubhai Ambani Life Sciences Center which is located on a 20 acre plot in Navi Mumbai. The Clinical Research Services are situated in a facility in Bangalore. The Biofuels agronomy research is conducted at farms located in Kakinada, Nagothane and Gandhar. Taking forth its motto of diversity and depth of initiatives Reliance Life Sciences has a team of PH.Ds,  M.Ds, Engineers and post graduates in sciences. One-third of its employees are women.

Important past events –

Reliance GeneMedix Plc is a UK-based subsidiary of Reliance Life Sciences. It has emerged from the acquisition of the UK based biotech company Genemedix Plc in order to develop biosimilars for the European market. The manufacturing facility for Reliance GeneMedix Plc is situated in Ireland. The first product from this association is slated to be the biosimilar version of Erythropoietin which is used in kidney-related applications and in patients under chemotherapy.

Reliance Life Sciences has filed over 281 patents at both national and international levels that cover the entire spectrum of its research and development activities. Reliance Life Sciences is also working on the development of novel therapeutics that are aimed at the treatment of cancer, infectious diseases, inflammatory disorders, ocular disorders and neurodegenerative disorders. This discovery program is based on siRNA and monoclonal antibodies.

Reliance Life Sciences made an important contribution towards surgery of Hemophiliac patients in 2006. Total Knee replacement surgery was previously viewed as too risky and complex in Hemophiliac patients but is now possible with Anti-Hemophilic Factor VIII that was made available by Reliance Life Sciences.

Reliance Life Sciences also plans to foray into the global generic drug space with the introduction of its first generic drug in the international market in 2009. It will produce Active Pharmaceuticals Ingredients (APIs) and generic medicines for the international market including the US and Europe.

Products:

Reliance Life Sciences has a variety of medical and plant products to offer.
It offers the following through its medical products and services line:

Medical Products:
Biopharmaceuticals

Plasma Proteins –

• ReliSeal: It is a quick acting fibrin sealant derived from human blood plasma with hemostatic sealing and adhesive properties. It can be used in surgical procedures to curb bleeding, seal tissues and heal wounds by mimicking the final stage of the natural clotting mechanism.

• AlbuRel: It is human normal albumin and is used for the restoration and maintenance of circulating blood volume where there is volume deficiency and use of colloid oncotic pressure is required.

• ImmunoRel: It is derived from pooled human plasma. Its U.S. FDA approved indications are in primary immunodeficiency, ITP, Kawasaki disease, CLL, paediatric HIV infection, bone marrow transplantation. Its off-label uses are for GB syndrome, Multifocal Motor Neuropathy, CIDP, Lambert Eaton Myasthenic syndrome, Myasthenia Gravis, Neonatal Sepsis, Polymyositis and Dermatomyositis.

• HemoRel: It is an intermediate pure factor VII and is indicated for patients diagnosed with the clotting disorder of haemophilia A, who have a deficiency of factor VIII. It was successfully used in the total knee replacement of a haemophilia patient in 2006.

• ReliPlasma: It is pooled viral inactivated plasma which is used as a substitute of fresh frozen plasma and effectively eliminates enveloped viruses like HBV, HCV and HIV from plasma. Treatment of plasma with Reliplasma has shown a reduction of the frequency of both transfusion transmitted infections and non-infectious complications. It can be administered for treatment of various clotting disorders, TTP and bleeding related to use of drugs such as warfarin.

Biosimilars

• Reliferon: It assists the human immune response system by activating natural killer cells and macrophages, promoting antigen presentation to lymphocytes and thereby inducing resistance of host cells against foreign agents and also has direct anti-viral effects. It is used in the treatment of more than 14 malignancies and viral diseases which includes adjuvant therapy in metastatic melanoma, condyloma acuminata, Kaposi’s sarcoma and most significantly hepatitis B and C.

• ReliPoietin: It works as a growth hormone and also stimulates the production of red blood cells from the hematopoietic stem cells found in the bone marrow. It is solely produced by kidney cells, and therefore, any functional damage to the kidneys can result in the deficiency of EPO as well as reduction in the production of the RBC pool that eventually leads to anemia. It is used to reverse anemic conditions that arise due to the body’s inability to produce the required amount of erythropoietin, and thereby reduce the pool of red blood cells. It is used as support therapy to reduce the number of dialysis required by renal failure patients and better tolerance of chemotherapy and reduced number of blood transfusions in case of cancer patients.

• ReliGrast: It is a human recombinant Granulocyte Colony Stimulating Factor which is a specific growth factor that is known to stimulate the production of neutrophils that are a type of white blood cells in the body that are necessary for fighting infections. It is used to therapeutically reverse neutropenic conditions. It can be used in chemotherapy induced neutropenia, AIDS-associated neutropenia, congenital and cyclic idiopathic neutropenia.

Regenrative Medicine:

• Reli-Heal G: It is sterile gauze that provides a moist environment for wounds to heal. Its benefits are a decreased rate of infection, autolytic debridement of slough and necrotic tissue as well as minimal pain or trauma to the wound bed, whenever it is applied or removed.

Pharmaceuticals

• TemoRel: It is a chemotherapeutic agent that is indicated for the treatment of newly diagnosed glioblastoma multiforme (GBM) and refractory anaplastic astrocytoma. GBM and anaplastic astrocytoma are high grades of brain tumors or gliomas.

Medical Services -
Regenerative Medicine

• Relicord: Relicord S is a sibling donor program and Relicord A is an allogenic voluntary donor program that is offered to patients who suffer from blood related disorders and need transplantation. The Cord Blood Repository for Reliance Life Sciences holds a license from the Food and Drug Administration of the Government of India.

• ReliNethra: It is the first stem cell based therapy in India and is indicated for unilateral partial and total limbal stem cell deficiency conditions like chemical burns, thermal burns, mechanical injuries to cornea, contact lens-induced keratopathy and more.

Molecular Medicine

• Relix: It is a range of molecular diagnostic and genetic testing services used for diagnosing several infectious diseases and genetic disorders like tuberculosis, hepatitis B and C, dengue virus, typhoid, amniotic fluid karyotyping, cord blood karyotyping and more.

For its plant products and services line Reliance Life Sciences offers:

Plant Products -

• Tissue Cultured Plants: To cultivate a wide variety of plants for various uses in categories like horticulture, floriculture, ornamental plants, plantation, bio-diesel and medicinal and aromatic plants.

• ReliCare: It is Aloe Vera spray dried powder that can be useful in cosmetic applications and nutraceuticals applications.

• Rellure: It is Kesar Mango pulp made from the Kesar mangoes grown at the Reliance orchard in Jamnagar and is marketed for use as an ingredient in milk shakes, ice cream and mango juice preparations.

Plant Services -

• Cultivation Technology: Reliance Life Sciences uses a detailed package of practices for tissue cultured plant-based plantations as well as it has timely field inspections along with advice from qualified and experienced scientists.

• Contract Production & Research: Through this Reliance Life Sciences offers contract production of plants that uses either the protocol supplied by the client or the available in-house protocols. Reliance Life Sciences also initiates and micro-propagates cultures supplied by customers. It also develops commercially viable tissue culture production protocols on request.

Business Divisions

The Plant Tissue Culture Group is to provide micro-propagation of plants, mass multiplication of elite varieties and contract production of client-specific plant varieties.

ReGenesis is an assisted reproduction facility of Reliance Life Sciences which is situated in Worli, Mumbai. It is a centre for assisted reproduction, endoscopy and fetal medicine.

The Industrial Biotechnology initiative encompasses Biopolymers and Biochemicals and is involved in bioprocess innovation and development from process inception to industrial level production.

Reliance Life Sciences pursues research programs in Enzymology in Industrial Enzymes for Biofuels and Therapeutic Enzymes.

Reliance Institute of Life Sciences is a part of the initiative by Reliance Life Sciences. It is a not-for-profit organization that is sponsored by the Dhirubhai Ambani Foundation. The main focus of Reliance Institute of Life Sciences is to develop competent biotechnology that will be of use to the entire industry. The Institute has on offer a wide range of competency development programs and diploma programs in both biotherapeutics and clinical research.

Corporate Structure:
The company board of directors, important executives and other people instrumental to the success of the company

Stock : Listing and Performance over time – No separate listing on any stock exchange.

Slogans/Mission Statements -

Vision of attaining global leadership through innovative and cost-effective solutions for a better life.

Subsidiaries:

Reliance Biopharmaceuticals Private Limited: An initiative to research, develop and market products in categories of Blood Plasma Proteins, Biosimilars and Monoclonal Antibodies.

Reliance Pharmaceuticals Private Limited: To develop active pharmaceutical ingredients and formulations for global markets.

Reliance Clinical Research Services: To cater to drug development needs of pharmaceutical, biopharmaceutical, medical device and nutraceutical companies from USA, EU, Japan, India and other parts of the world. To offer CRO in domains like medical writing, biostatistics, clinical data management, etc.

Reliance Biofuels Private Limited: It is working towards developing an India-centric biofuels initiative that covers Biodiesel from Jatropha and other non-food oil seed crops, Bioethanol from cellulosic biomass and Biobutanol from cellulosic biomass.

Sponsorships: Only as part of the Reliance Group